AstraZeneca: latest news - GoINPHARMA
Tuesday, 11 December 2018 - 14:39

AstraZeneca

AstraZeneca’s Imfinzi fails another Phase III clinical trial

Astra Zeneca CEO Pascal Soriot’s position is more and more difficult. The French manager in 2015 convinced shareholders to reject a $118bn acquisition offer by Pfizer, arguing that independence would mean higher financial return to shareholders. The strategy developed by…

First rumors about radical top management reshuffle at Astra Zeneca

The Sunday Times yesterday reported that AstraZeneca has started working on a replacement plan for CEO Pascal Soriot and CFO Marc Dunoyerl, due to pressure by some main shareholders, dissatisfied with the French manager’s work. The British weekly mentions Mene…

AstraZeneca sells Synagis for 1.5 billion dollars

AstraZeneca’s shares rose over 1% today (London) as the group led by Pascal Soriot announced that it has sold to Swedish Orphan Biovitrum AB (SOBI) the rights to market its therapy for respiratory diseases Synagis in the US . The…

AstraZeneca announces new excellent clinical data from Farxiga (diabetes)

Astra Zeneca announced at the American Heart Association Congress, which closed in Chicago yesterday, data from the DECLARE-TIM trial, aimed at assessing Farxiga (dapagliflozin) on patients with diabetes. The results show that Farxiga significantly reduced (-17%) the risk of hospitalization…

AstraZeneca invests almost 1 billion in partnership with Innate Pharma

AstraZeneca has announced it has expanded its scientific cooperation agreement with biotech Innate Pharma, signed in 2015. By expanding the agreement, the British-Swedish group seeks to strengthen its portfolio of immunotherapies for cancer. Specifically, the deal provides AstraZeneca with a…

Positive clinical results from AstraZeneca’s Lynparza (ovarian cancer)

AstraZeneca’s PR department doesn’t stop, neither on Sunday–this afternoon, it issued a release announcing that cancer drug Lynparza (PARP inhibitor) has shown efficacy on women with newly-diagnosed ovarian carcinoma. Specifically, scientists from the Britain-based group have introduced at the European…

Pascal Soriot voices disappointment over his pay package

AstraZeneca CEO Pascal Soriot 4 years ago achieved to convince the company’s shareholders and the British government to decline Pfizer’s  acquisition bid, worth $118bn. At that time, Soriot ensured financial return and job protection levels that Pfizer wasn’t able to…

AstraZeneca fails another Phase III clinical trial (Lupus)

AstraZeneca’s shares have declined almost 2% as the group led by Pascal Soriot has announced that the investigational therapy anifrolumab had failed to reach its primary endpoints in the Phase III Tulip clinical trial conducted on 460 patients with systemic…

Investors believe in AstraZeneca

The German economic-financial weekly Euro am Sonntag yesterday published a long article about AstraZeneca’s financial performance and the expectations for its future. AstraZeneca’s shares have increased by 15% YTD  and 32% over the last 12 months (London); they have recently…

Another disappointing quarter for AstraZeneca, shares drop 2%

UK-based pharmaceutical group AstraZeneca today announced its Q1 2018 results, before trading started in Europe. Investors did not approve the performance and AstraZeneca’s shares soon declined 2.3% as trading started. What raises most concern is the 4% sales drop (-9%…

Renewed speculation on Pfizer targeting AstraZeneca

AstraZeneca’s shares yesterday resumed an upward trend (London) as Streetinsider suggested that Pfizer could attempt a takeover to the UK-based group AstraZeneca. Many  analysts think that Pfizer is pursuing a major acquisition and companies such as Shire, Allergan, BMS and–more…

Ionis sells NASH therapy to AstraZeneca for $300m

California-based Ionis Pharmaceuticals has announced it has licensed to AstraZeneca its investigational therapy Ionis-AZ6-2.5, developed to treat patients with Non-Alcoholic Steatohepatitis (NASH). This is the third therapy obtained from the partnership between the firms. Under the terms of the agreement,…

Ups and downs in AstraZeneca’s annual results

AstraZeneca has announced today its 2017 results to the financial community. Sales declined by 2% in 2017 to $22.46bn, and reported operating profit was down 25%, due to the higher costs to be born to launch new drugs. AstraZeneca’s press…

AstraZeneca’s asthma therapy approved in Europe as well

MedImmune’s (AstraZeneca) monoclonal antibody benralizumab has been approved in Europe for the treatment of severe asthma. The drug was recommended by EMA CHMP last November and was approved in the US in the same month. Benralizumab will be available as…

Vectura targeted by AstraZeneca and Novartis (GBP700m)

The Daily Telegraph has reported today that UK-based Vectura Group is targeted by AstraZeneca. According to rumors circulating yesterday, instead, Novartis–a partner of Vectura’s–is planning to acquire it completely. Vectura’s shares have lost over 21% of their value since January…

Leif Johansson, AstraZeneca’s chairman, on possible Brexit aftermaths

Leif Johansson, chairman of pharmaceutical group AstraZeneca, has addressed in an interview to Handelsblatt the aftermaths of Brexit in the pharma sector. Johansson, 66, from Sweden, MSc in mechanical engineering and former chairman of Ericsson group, has said that AstraZeneca…

Dizal Pharmaceutical, new JV created by AstraZeneca and Chinese partner

AstraZeneca has announced today it has entered into an agreement with China-based Future Industry Investment Fund (FIIF), in order to establish a joint venture named Dizal Pharmaceutical. The newly-created JV will focus on drug discovery – which is consistent with…

AstraZeneca reports third quarter results exceeding expectations

UK-based AstraZeneca today presented its Q3 results to investors and analysts. The data exceeded market expectations, thus the company’s management took the opportunity to improve the expected sales for 2017. Sales rose by 9% over Q3 2016, to $6.2bn (vs…

Significant news from AstraZeneca

AstraZeneca has reported results from the Phase III STRATOS 2 clinical trial, designed to assess tralokinumab, an anti-interleukin-13 (IL-13) monoclonal antibody in patients with uncontrolled asthma. The data show that tralokinumab does not provide any advantage on conventional therapies. Denmark-based…